4.8 Article

Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

期刊

CANCER CELL
卷 22, 期 2, 页码 153-166

出版社

CELL PRESS
DOI: 10.1016/j.ccr.2012.06.005

关键词

-

资金

  1. NCI
  2. NIH, Therapeutically Applicable Research to Generate Effective Treatments initiative [N01-C0-12400]
  3. Children's Oncology Group Chair's award [CA098543]
  4. National Cancer Institute Strategic Partnering to Evaluate Cancer Signatures Program [CA114762]
  5. NIH Cancer Center Core Grant [CA21765]
  6. St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project
  7. Stand Up To Cancer Innovative Research Grant
  8. American Lebanese Syrian Associated Charities of St. Jude Children's Research Hospital
  9. National Health and Medical Research Council (Australia)
  10. Haematology Society of Australia
  11. New Zealand Novartis New Investigator Scholarship
  12. MSFHR
  13. [U10 CA98543]
  14. [U10 CA98413]
  15. [U24 CA114766]

向作者/读者索取更多资源

Genomic profiling has identified a subtype of high-risk B-progenitor acute lymphoblastic leukemia (B-ALL) with alteration of IKZF1, a gene expression profile similar to BCR-ABL1-positive ALL and poor outcome (Ph-like ALL). The genetic alterations that activate kinase signaling in Ph-like ALL are poorly understood. We performed transcriptome and whole genome sequencing on 15 cases of Ph-like ALL and identified rearrangements involving ABL1, JAK2, PDGFRB, CRLF2, and EPOR, activating mutations of IL7R and FLT3, and deletion of SH2B3, which encodes the JAK2-negative regulator LNK. Importantly, several of these alterations induce transformation that is attenuated with tyrosine kinase inhibitors, suggesting the treatment outcome of these patients may be improved with targeted therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据